Valiglurax

CAS No. 1976050-09-5

Valiglurax( —— )

Catalog No. M34729 CAS No. 1976050-09-5

Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 Get Quote
10MG 69 Get Quote
25MG 144 Get Quote
50MG 247 Get Quote
100MG 353 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Valiglurax
  • Note
    Research use only, not for human use.
  • Brief Description
    Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.
  • Description
    Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC50 values of 64.6 nM and 197 nM for hmGlu4/Gqi5 and rmGlu4 GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease.
  • In Vitro
    ——
  • In Vivo
    Animal Model:haloperidol-induced catalepsy (HIC) in rats Dosage:0.3-30 mg/kg Administration:Oral administration Result:Reversed haloperidol (HY-14538)-induced catalepsy (HIC) in rats in a dose-dependent manner.
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    GluR
  • Recptor
    GluR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1976050-09-5
  • Formula Weight
    329.28
  • Molecular Formula
    C16H10F3N5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (253.07 mM; Ultrasonic (<60°C)
  • SMILES
    C(F)(F)(F)C=1C2=C(C=C(NC=3C=4C(NN3)=NC=CC4)C=C2)C=CN1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Panarese JD, et, al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260.?
molnova catalog
related products
  • cis-PDA

    cis-PDA is a general ionotropic receptor antagonist. cis-PDA acts by blocking NMDA, AMPA, and kainate-mediated responses.

  • FITM

    FITM is a potent negative allosteric modulator of mGlu1 receptor(Ki : 2.5 nM).

  • CX717

    CX 717 is a positive allosteric modulator of the AMPA receptor with antidepressant-like effects and potential use in adult attention deficit hyperactivity disorder (ADHD) research .